Charles Héaulmé’s sick leave is due to a cancer with a very good prognosis.
Huhtamaki managing director Charles Héaulmé will remain on sick leave, the company informs.
The reason for the sick leave is a brain tumor that requires a period of treatment, but which has a very good treatment prognosis.
Héaulmé’s sick leave will begin in early January and he is expected to return to work in the second quarter of next year.
CEO the CFO has been appointed as interim deputy Thomas Geust from the beginning of January.
Geust will report to the Board and serve as CEO until the end of Héaulme’s sick leave. An interim chief operating officer has been appointed Eric Le Lay.
Huhtamaki manufactures consumer packaging, including disposable containers and food packaging.
.
#Companies #Huhtamakis #CEO #sick #leave #due #brain #tumor
